News stories about Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novelion Therapeutics earned a news impact score of 0.07 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.1548347045112 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several brokerages have recently commented on NVLN. Royal Bank Of Canada set a $9.00 price objective on shares of Novelion Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, August 8th. ValuEngine downgraded shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Finally, Zacks Investment Research downgraded shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th.

Novelion Therapeutics (NASDAQ NVLN) traded down $0.03 during midday trading on Thursday, reaching $3.89. 31,300 shares of the company traded hands, compared to its average volume of 97,003. Novelion Therapeutics has a twelve month low of $3.60 and a twelve month high of $13.80. The company has a debt-to-equity ratio of 6.53, a current ratio of 1.45 and a quick ratio of 1.28.

TRADEMARK VIOLATION WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at

About Novelion Therapeutics

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Insider Buying and Selling by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Receive News & Ratings for Novelion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics Inc. and related companies with's FREE daily email newsletter.